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Arginase added to culture medium reduced arginine to negligible levels within B6 h, and enzyme activity persisted relatively
undiminished for at least 3 days. Human and bovine arginase proved equally effective. The response of normal cells was to enter G1
(G0) arrest, from which most of the cells could be recovered weeks later. In contrast, malignant cell lines treated with unpegylated or
pegylated enzyme resulted in cell death on a massive scale within 3 – 5 days, with a very low to negligible percentage of cells
(o0.01%) being recoverable on restoration with arginine. Although pegylation resulted in a 40% drop in specific activity, arginase was
considerably more stable and remained active forb8 days. Arginine decarboxylase caused malignant cell arrest at the same units per
millilitre as arginase. Its breakdown product, agmatine, was relatively nontoxic in the presence of arginine, but exacerbated cell death
above millimolar concentration in its absence. Although ornithine failed to rescue cells from deprivation, citrulline recovered cells in all
cases, although less well in fast-growing tumour cell populations, whereas readdition of arginine failed to work unless a complete
medium change was given (because of the persistence of the enzymes in the medium catabolising its destruction). The advantages
and disadvantages of these two arginine-catabolising enzymes are discussed, and compared with arginine deiminase.
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A major aim of our work has been to lower arginine levels in vitro
and in vivo to arrest the growth of cells, and selectively cause the
death of cells of malignant phenotype (Scott et al, 2000; Wheatley,
1998). Normal cells with stringent checkpoints respond to nutrient
deprivation by arresting cells in G0, from which the majority can
be recovered several weeks later. Lowering arginine levels presents
no difficulty in culture, and most previous studies have
concentrated on arginine-deficient media containing dialysed
serum. A closer comparison with in vivo work would be to
degrade arginine in situ with enzymes, the three main contenders
being arginase, arginine decarboxylase and arginine deminase. The
ultimate objective is to sustain free plasma or medium arginine at
o5 mM (preferably B1 mM) long enough to procure cell death,
which is clearly going to be much more difficult to accomplish in
vivo than in culture. Our present experiments were designed to
give further insight into the comparative efficacy of two of the
arginine-catabolising enzymes in vitro, viz arginase and arginine
decarboxylase, which could lead to improvements in their
deployment in the in vivo treatment of cancer. Arginine deiminase
will only be discussed here, because it generates ammonia and its
toxic action on cells presents a problem that makes it less useful as
a potential therapeutic agent (Wheatley and Campbell, 2002). The
important enzymes of arginine metabolism relevant in the present
studies and their main properties are given in Table 1.
The specific objectives in the experiments reported here were to
demonstrate that (i) arginase will quickly and effectively mop up
all free arginine in culture medium for a considerable time
measured in days after a single treatment, (ii) citrulline in the
absence of arginine will generate arginine, which is not accessible
to degrading enzymes in the medium (i.e. the ‘free’ arginine does
not equilibrate with the medium), and (iii) different cell types
clearly have different citrulline requirements, which correlates with
growth rate. Thus, the rate of conversion of citrulline to arginine
becomes the rate-limiting step, and this becomes most obvious the
faster the cells grow.
Removal of arginine from the body under normal physiological
conditions results in a powerful boost to the homeostatic
mechanisms by which free amino-acid levels in the blood are
restored. In addition to the release of considerable amounts of free
amino acids liberated by skeletal muscle breakdown, the gut/
kidney axis (Wu and Morris, 1998) is involved in arginine
metabolism, since citrulline biosynthesis occurs in the former
organ and is converted to arginine in the urea cycle by the
actions of argininosuccinate synthetase (AS; EC 6.3.4.5) and
argininosuccinate lyase (AL; EC 4.3.2.1) in the kidney (Schimke,
1964).
Some cells are clearly more adept than others at circumventing
arginine deficiency by recycling enzyme products. The conversion
of ornithine to citrulline requires ornithine carbamoyl transferase
Received 28 June 2002; revised 24 September 2002; accepted 1 October
2002
*Correspondence: Dr D Wheatley; E-mail: wheatley@abdn.ac.uk
British Journal of Cancer (2003) 88, 613 – 623
& 2003 Cancer Research UK All rights reserved 0007 – 0920/03 $25.00
www.bjcancer.com
E
x
p
e
ri
m
e
n
ta
l
T
h
e
ra
p
e
u
ti
c
s
(OCT; EC 2.1.3.3), but apart from normal hepatocytes and a few
minimal deviation hepatomas, most cultured cells cannot perform
this transfer (Sugimura et al, 1992), and therefore ornithine rarely
substitutes for arginine in culture (Eagle, 1955). On the other hand,
Eagle (1959) found that citrulline can substitute for arginine, and
this is so in all malignant and normal cells cultured in aeginine-
free medium (AFM) that we have so far investigated (Wheatley
et al, 2000). The question now is whether citrulline metabolism
interferes with or circumvents enzymatic efforts to reduce free
arginine to negligible levels in cultures.
Arginine has arguably the most complex metabolic pathways of
any amino acid within the cell and the body. It can be removed by
dietary restriction, dialysis or enzymatic destruction. The first
method has always presented problems in the preparation of
suitable diets, and of compliance (Wheatley, 1998). The second is
experimental, and the technology needed to achieve low blood
arginine is highly complicated (Wheatley et al, 2002), although it is
being further developed (Shettigar, 1990). The third approach has
been adopted by a number of groups, and involves enzymatic
degradation of arginine in situ (Bach and Swaine, 1965; Storr and
Burton, 1974; Terayama et al, 1982; Gong et al, 2000; Miyazaki et al,
1990). In all probability, the combined use of these strategies will
be required.
An adequate supply of arginine is vital for growth, and its
removal in early life seriously stunts normal development (Daniel
and Krishnan, 1967). This might later be reflected by limited
tumour growth in adult animals, where supply again falls short of
demand; hence, the danger is that arginine supplementation
enhances tumour growth and makes matters worse (Bach and
Lasnitski, 1947; Leffert and Paul, 1973). The effects of arginine
withdrawal become manifest more quickly than that of any other
amino-acid withdrawal, with the additional advantage that tumour
cell death occurs quickly without further intervention (Wheatley
et al, 2000). For tumour regression to occur, arginine probably
needs to be down at micromolar levels for 7 – 8 days, although
lymphomas and leukaemias may succumb in 2 – 4 days (Storr and
Burton, 1974; Takaku et al, 1992). Although we have already
reported on the effects of AFM with 25 cell lines (Scott et al, 2000),
comparative studies on the efficacy of arginine-catabolising
enzymes added to normal medium (enzyme-treated medium, or
ETM) were undertaken as an alternative means of achieving a
deficient state.
MATERIALS AND METHODS
Cell culture
L1210 cells (murine lymphoblastic leukaemia) were maintained in
flasks at between 0.1 and 3 106 cells ml1 in exponential phase
growth (generation time B15 h) in RPMI 1640 medium (Life
Technologies, Paisley, UK) at 371C in a humidified atmosphere of
5% CO2. For experiments, they were set out in 2 ml of culture
medium at 5 104 cells ml1 in 12-well plates. HeLa cells (cervical
carcinoma) and human diploid fibroblasts (the latter being early
passage numbers from primary cultures grown from human skin
taken at breast reduction) were seeded at 50 000 ml1 in flasks or
plates in a similar manner previously described in Scott et al
(2000). The cells were used at the lowest passage numbers that
would provide adequate stocks of cells, they were checked as
mycoplasm free, and they were authenticated from source, as
required by the UKCCCR ‘Guidelines on the use of cell lines in
cancer research’ (ohttp://ukcccr.icnet.uk4).
Basic RPMI 1640 medium (Sigma, Poole, Dorset, UK) lacking
the following supplements was prepared by the addition of these
compounds to the stated final concentrations: 4 mM L-glutamine,
0.4 mM L-arginine, 0.2 mM L-cystine, 11.1 mM D-glucose, 0.2 mM L-
inositol, 0.38 mM L-leucine, 0.1 mM L-methionine. Foetal calf serum
(10%) (Harlan, Crawley Down, UK) was added for stock growth,
but 5% dialysed serum was used in experimental plates. AFM
omitted L-arginine from the final medium formulation. Normal
(positive) controls were given AFM to which arginine had been
restored at 0.4 mM, ensuring that the same medium was used
throughout, with negative controls given placebo (vehicle) only,
and cultures treated with other amino acids received these in lieu
of arginine. Cells were counted electronically with a Coulter
Counter at regular (usually daily) intervals. [Note: RPMI 1640
normally has an arginine concentration of 1.0 or 1.1 mM. However,
in order to compare with most of our previous studies where
arginine was kept at 0.4 mM (see Scott et al, 2000), this same (more
critical) level was used in the present studies.)
Enzyme preparations (for additional data, see Table 2)
Arginase Bovine liver arginase was obtained in its native form
from Sigma with an activity of approximately 200 units mg1 and
was used in the experiments indicated without any further
activation steps. Human recombinant arginase was obtained from
Dr Ikemoto, Kyoto, Japan, with an activity of B1500 – 2000 uni-
ts mg1 protein. Prior to use, the enzyme was heat activated at
601C for 10 min in the presence of Mn2+ ions, as instructed by Dr
Ikemoto (personal communication). In order to prolong the half-
life of the enzyme, it was also pegylated with cyanuric chloride-
activated polyethylene glycol (Sigma) at room temperature, pH 9.0,
for 30 min using the method of Savoca et al (1984). The resulting
enzyme was dialysed against 5 l of 1 phosphate-buffered saline
(PBS) to remove excess polyethylene glycol with a Hemoflow F40S
capillary dialyser (Fresenius Medical Care, Bad Homburg,
Germany). The recovered enzyme was filtered through a 0.2 mm
filter (Nalgene, Nalge Co., Rochester, NY, USA) and stored at
201C ready for use.
Arginine decarboxylase Sigma arginine decarboxylase from E.coli
was used, which had a specific activity decidedly lower than
arginase (see Table 2). However, human recombinant arginine
decarboxylase expressed in E.coli, obtained frozen from Professor
Steven M Boyle (Virginia Polytechnic Institute and State Uni-
versity, Blacksburg, VA, USA), had an even lower activity of
B2.5 units mg1. Owing to the latter preparation having a high
protein content, the enzyme precipitated on thawing. Prior to use,
the solution was warmed to 181C and adjusted to 20 mM with
respect to dithiothreitol (DTT). After incubating the solution on
ice for 10 min, the preparation was centrifuged at 10 000 g for
10 min and the supernatant recovered. The supernatant was
Table 1 Properties of some of the more relevant arginine-metabolising enzymes in this study
Enzyme EC number Substrate(s) Cofactors/ions/etc Products Km (mM)
Arginase 3.5.3.1 Arginine Mn2+ Ornithine and urea 10.5
Arginine decarboxylase 4.1.1.19 Arginine Pyridoxal phosphate Agmatine and CO2 B1
Arginine deiminase 3.5.3.6 Arginine Mg2 Citrulline and NH3 B0.1–0.2
Nitric oxide synthase 1.14.13.39 Arginine (made from citrulline) and O2 NADPH-NADP+ NO and citrulline 0.03
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diluted 1 : 10 and dialysed against 0.9% saline along with the
cofactors pyridoxal-5-phosphate (1.2 mM) and MgCl2 (4 mM).
Enzyme activity
Enzyme activities were analysed in vitro over time at 371C in a
humidified atmosphere of 5% CO2. Arginase was added to basic
RPMI medium (without foetal calf serum) with L-arginine at
1.1 mM. The reaction was stopped at selected time points by the
addition of 10% sulphosalicyclic acid (Sigma), which precipitated
the protein at 41C for 30 min. The resulting samples were
centrifuged at 13 000 rpm for 10 min in a microcentrifuge and
the supernatant was filtered through a MillexR-GV 0.22 mm filter
(Millipore, Bedford, MA, USA). Arginine and ornithine were
measured using a Biochrome 20 Amino Acid Analyser (Amersham
Pharmacia Biotech, Cambridge, UK). Arginase activity was
calculated in units, 1 unit being the amount of enzyme catabolising
1 mmol of arginine to ornithine (and urea) per minute per
milligram of protein. Similarly, a unit of arginine decarboxylase
was the amount of enzyme catabolising 1 mmol of arginine to
agmatine per minute per milligram of protein.
Ornithine assay
Arginase activity was also assayed by the method of Ochoa et al
(2000), which uses ninhydrin to detect the ornithine concentration,
within each sample by a colorimetric procedure measured on the
spectrophotometer at B515 nm wavelength (Chinard, 1952). The
specific activity of arginase can therefore be defined as the amount
of ornithine (mmol) per minute per milligram of protein produced,
calibrated against known standards within the range 10–100 mM.
Protein analysis
An adaptation of the Lowry method (Oyama and Eagle, 1952) was
used in conjunction with the above ornithine assay to determine
accurately the protein concentrations of the various samples. The
specific activities of the enzymes were required for accurate
comparisons between the different preparations and batches.
Statistics
Comparisons have been analysed by the Student’s ‘t’-test only
where appropriate, with significance being taken as Po0.05. Small
deviations have not been subject to rigorous inspection at this
stage because these will not provide the level of discrimination
sought between malignant and normal cell responses.
RESULTS
Human diploid fibroblasts
Fibroblasts growing with a generation time of about 36 h were
arrested in AFM. The cell number remained almost constant for
46 days (Figure 1A), although sometimes a small initial fall in
number was seen. The cells could be kept at 371C under these
deprivation conditions for at least 3 weeks and probably
considerably longer without serious loss of viability, although we
show in Figure 1B rescue following a medium change into
arginine-containing medium after 5 days of deprivation. There
was little cell loss early in the rescue, but recovery required 5 – 6
days before growth kinetics approached those of the positive
controls (which by this time had reached stationary phase).
Almost identical data were recorded for cultures in complete
medium treated with either bovine arginase or E. coli arginine
decarboxylase (hereafter ETM1 and ETM2, respectively) in situ
(Figure 1A). Arrested cells entered G1/G0, as previously described
in AFM by Scott et al (2000). In terms of cell growth inhibition
kinetics sampled after 3 days treatment, arginase was active at
0.25 – 0.5 units ml1 (IC50B0.3 units ml
1), the inhibition becom-
ing increasingly felt with time. It was more immediately and
completely inhibitory at 1 unit ml1 and above, but with higher
enzyme concentrations of up to 5 units ml1, depression of cell
growth occurred earlier. The same was true of arginine decarbox-
ylase (Figure 1A), but dose – response curves will be dealt with in
regard to the malignant cell lines for L1210 cells below. However,
these results refer here to slow-growing fibroblasts, and we already
know (Wheatley et al, 2002) that 1 unit ml1 arginase can reduce
arginine to negligible levels in a matter of a B3 – 6 h in vitro (see
below and Discussion).
Citrulline added to the ETM1-treated cultures without removal
of the enzyme permitted growth at approximately control rates
(Pb0.05), and at the same rate in AFM cultures (only one curve
shown in Figure 1B for the sake of clarity). It was noteworthy that
arginine failed to restore cell growth in ETM1-treated cultures.
Data for ornithine ‘rescue’ have been included in Figure 1A, but
will be omitted throughout the rest of these studies because it (a)
Table 2 Details of relevant and associated enzyme preparations
Enzyme preparation Source Species Km (mM) Specific activity U
Arginase
Sigma Bovine (articular cartilage) 5–10 192
Ikemoto Human (recombinant) 5–15 1482
Ikemoto; pegylated Human (recombinant) ND 595
Arginine decarboxylase
Sigma E. coli B1 5–15
Boyle Human (recombinant) B1 2.5
Boyle; pegylated Human (recombinant) Inactive inactive
Extracts (arginase) Liver Bovine 5–10 0.5–3
Liver Human 5–10 1
Arginine deiminase (Gong et al, 2000) See Holley (1967) Human B0.1–0.2
NO synthetase (Chang et al, 2001) See Wheatley (1998) Human 0.03
Arginase – amount of enzyme required to convert 1 mmol arginine to ornithine and urea at pH 9.5 and 371C. Arginine decarboxylase – amount of enzyme required to convert
1 mmol arginine to agmatine and CO2 at pH 5.2 and 371C. Specific activity refers to arginase activity, and its level depends on extraction procedure, with preparations that have
varied as much as 10-fold from sample to sample. Data for liver extracts, arginine deiminase and nitric oxide synthase are included only for information and comparison, because
the affinities of the latter two can be very much higher (lower Km) than for the other enzymes.
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allowed no recovery under any of the deprivation conditions we
have used (in agreement with earlier findings of Wheatley et al,
2000), and (b) lacked any observable inhibition of ETM1, on which
it is supposed to act by feedback inhibition (see Discussion).
ETM2 had a similar effect at 1 unit ml1 to arginase (Figure 1A),
and also responded to citrulline in an almost identical manner
(Figure 1B, curve not shown for the sake of clarity). Arginine once
again failed to allow recovery of ETM2-treated cultures in the
continued presence of the enzyme, although the recovery of AFM-
treated cells was identical to the positive control. With regard to
the latter, recovery after a 5-day treatment with AFM required 43
days to re-establish normal growth kinetics in fibroblasts
(Figure 1C).
HeLa cells
The behaviour of HeLa cells (generation time 23 – 24 h) to the
presence of ETM1 and ETM2 was also very similar to our previous
findings using only AFM, and are included in the current
experiments for comparative purposes (Figure 2A). After the
second day, cell death became progressively more obvious and by
5 days, few, if any, cells remained intact except for some large
multinucleated cells (Figure 3A and B). The effective dose –
response curve was similar to that of fibroblasts, and citrulline
circumvented the effects of AFM and ETM1, but here a
significantly reduced growth rate of HeLa cells given 0.4 mM
citrulline was observed, that is a level corresponding to the
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Figure 1 (A) Growth kinetics of human diploid fibroblasts in (’) arginine-containing medium (positive controls), (&) AFM, and (J) arginine-containing
medium plus 1 unit ml1 arginase, or (m) the same except with arginine decarboxylase at 1 unit ml1, starting at day 1 (the latter was controlled with its own
vehicle without arginine present in the curve with the n symbols). The total number of cells in each of three wells was averaged at each time-point, and the
bars given are 1 s.d. around the mean. The significance of the differences between (’) and (J) or (m) is very highly significant (Po0.001), but the
differences between (&), (n) and (J) are not significant. (B) Growth kinetics as in (A), but for cells with attempted rescue in the continued presence of
the enzyme of the arginase-treated fibroblast cultures with 0.4 mM arginine (J), 0.4 mM citrulline (K) or 0.4 mM ornithine (m). The difference between the
positive control and the citrulline rescued cells was not significant (Pb0.05). (C) Recovery of fibroblast from 5 days of arginine deprivation prior to the
addition of 0.4 mM arginine to the culture medium without a medium change. (’) Positive controls that have had AFM but arginine restored immediately
after a medium change at day 1, compared with a second group (&) in which arginine was restored only on day 6, that is, after 5 days of complete arginine
deprivation. Cell loss during this whole experiment was minimal.
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0.4 mM arginine used throughout this work (Figure 2A,
Po0.0540.01). Once again, adding arginine to cultures treated
with enzymes failed to rescue growth because, unlike citrulline, it
was quickly degraded.
The response of HeLa to arginine decarboxylase was very similar
to that seen in fibroblast cultures, with good inhibition seen at
1 unit ml1, but more immediate and obvious cell death occurred
within 4 days with 5 units ml1 (Figure 2B), although in terms of
cell growth arrest measured after 3 days, the dose-response curve
for ETM2 looks particularly sharp (see data below for L1210 cells).
It was noteworthy, however, that 0.1 units ml1 brought about cell
arrest and the start of cell death after 2 days (Po0.1) and a highly
significant fall by day 4 (P50.01), indicating persistence of the
enzyme as it gradually got to work with time (this enzyme being of
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Figure 2 (A) HeLa cells treated with arginase (J) at 1 unit ml1 compared with cells in AFM (&) or its positive control with arginine present at 0.4 mM
(’), as in Figure 1A. Neither arginine (m) nor ornithine (curve not shown) rescued the cells treated with arginase, but citrulline did (K), with the difference
between the open and the closed circle being very highly significant, and the difference between (’) and (K) just significant (Po0.05 but 40.01). Details
of the curves as above, with error bars of 1 s.d. around each mean value sometimes not appearing outside the symbol. (B) Effect of arginine decarboxylase
on HeLa cells growth in normal medium (’) or AFM (&). The dose–response effect of the enzyme can be seen after being added at day 1, showing that
the initial stages between day 1 and 2 gave a wide range of growth inhibition, see inset series labels. ADC was added at the following units per ml to normal
medium: m 0.1; n 0.5; K 1; J 5. It is noteworthy that the highest dose level (J) of 5 units ml1 was quickly and markedly effective (see Results for
probabilities, and Discussion for comments on dose–response relations). (C) Effects of agmatine–the product of arginine decarboxylase–on HeLa cells, as
tested in AFM, shown on a semi-log plot. The positive AFM control curve is (’), whereas the AFM (negative) control (&) proved the least affected of the
deprived cells, but concentrations of 41 mM agmatine in the absence of arginine were required to produce ‘significant’ damage, that is, 4 (m) and 10 mM
(n), respectively. Less effective were 0.4 mM (K) and 1.0 mM (J). The data are averages of means, s.d. bars cannot be given and therefore ‘significance’ has
no statistical validity, but a clear dose-dependent trend is seen.
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higher affinity but lower capacity than arginase). Recovery with
citrulline was effective, whereas arginine was again ineffective (the
data mimic that of arginase recovery and are therefore not shown
here).
To determine whether agmatine, the product of arginine
decarboxylase, might per se have some effect on cell growth, we
analysed it by adding agmatine as an exogenous preparation in the
presence and absence of arginine. In the presence of 0.4 mM
arginine, agmatine had no obvious effect, except some cytotoxicity
at 5 mM. In the absence of arginine, agmatine was decidedly
cytotoxic, progressively reducing HeLa cell number to well below
that of the negative controls (Po0.01) as the dose increased and
most notably at and above millimolar concentrations (Figure 2C;
see Discussion).
L1210 cells
A series of similar experiments were carried out with L1210 cells,
which have an exceedingly rapid growth rate (generation time
15 h) and often attain a final concentration of over 3 million cells
per millilitre in suspension in normal medium. Clearly, this cell
line has a considerably higher nutrient demand than HeLa cells,
and a far greater one than fibroblasts. The basic findings confirm
the above HeLa cell data, but the faster utilisation of arginine
Figure 3 (A) HeLa cells subject to arginase treatment for 5 days; virtually no intact cells remain present except for a small clump (arrow) in which a large
multinucleate cell is present. (B) Control HeLa cell culture in which no arginase was present for 5 days and has gone to confluence. (C) L1210 cells in a
settled suspension from a culture after 3 days of arginase treatment; the majority of particles are shrivelled cells or free nuclei, with a few intact cells still
present (small arrowheads), but several large, intact multinucleate (polyploid) cells are present in this particular field (large arrowheads). Nuclei remain in
culture when L1210 cells break down because of the paucity of lysosomal enzymes. (D) Control L1210 cells, seen in the plane of focus in suspension. The
images are all phase-contrast micrographs of living cultures. Magnifications are approximately  200 for all panels.
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meant that cell death was more rapid in its absence, whether by
AFM or ETM treatment (Figures 4A and B). Probability estimates
are given in the figure legends.
The dose–response curve for arginine decarboxylase (Figure 4C)
shows its considerable efficacy against L1210 cells after 3 days
treatment. Most cells were irrecoverable after 4 days of AFM or
ETM treatment. A few cells persisted, as shown by microscopic
examination, these being predominantly large multinucleated cells,
as seen with HeLa cell cultures (see Figure 3C and D, and
Discussion).
Citrulline rescued the cells under AFM and ETM1 (arginase)
or ETM2 (arginine decarboxylase) treatment, but arginine
could only rescue cells from AFM (Figures 4A and 5A). Of
interest is the finding that 0.4 mM arginine sustained normal
growth when returned to AFM medium shortly after the start
of incubation, but the kinetics of recovery were very significantly
0
200 000
400 000
600 000
800 000
0
200 000
400 000
600 000
100 000
300 000
500 000
0
500 000
1 500 000
2 500 000
1 000 000
2 000 000
0 31 42 31 4 52
Ce
lls
 p
er
 w
el
l
Ce
lls
 p
er
 w
el
l
Ce
lls
 p
er
 w
el
l
0
31 4 520
Time (days)
A
B
C
Concentration (units per ml)
Units per ml
Figure 4 (A) Dose–response curve showing the inhibition of L1210 cell growth by Sigma (bovine liver) arginase used in the experiment shown in Figure
9. This preparation had about half its original activity after storage for some months, but shows that at a putative strength of 1 unit ml1 (approximately equal
to 0.5 units ml1 of the original enzyme), it slowed cells after 3 days when cell counts were made, but not as immediately as a higher dose halted growth. The
lowest values towards the higher enzyme concentrations correspond to the original inoculum of L1210 cells per well. (B) Effect of 0.5 units ml1 arginase
(Sigma) on L1210 cells in suspension in arginine-containing medium given at day 1 (m). The positive and negative controls in AFM are given as before by the
symbols (’) and (&), respectively, but with dashed lines (P50.01). They show the expected responses. Enzyme-treated cultures (solid lines) and arginine
(m) follow the same curve as the arginase alone (&), but the arginase-treated culture given 0.4 mM citrulline (n) shows recovery. However, its growth is
B30% the rate of the positive control, the difference being highly significantly slower (P50.01). The symbols of the last curve have been reduced to enable
the 1 s.d. bars around the means of triplcate values to be seen. (C) Effect of arginine decarboxylase on L1210 cells in terms of the action of a Sigma
preparation. The enzyme was freshly prepared and highly active at 1 unit ml1 within the 3 days at which assessment was made (cf. Figure 6A). The lowest
value given here at the high concentrations corresponds approximately to the original inoculum density of the cells in each well (ie 100 000).
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reduced with 0.4 mM citrulline (Figure 5A; cf HeLa cells in
Figure 2A).
Recovery by removal of enzyme and arginine restoration
In the continuing presence of arginase, only large cells remained
intact in L1210 cultures (Figure 3C and D), from which
repopulation of the cultures on removal of the enzyme presumably
occurred (see Discussion). Among L1210 cells that had been
allowed to die for as long as 4 days in AFM, some began to show
signs of recovery between 3 and 6 days later in arginine-containing
medium, but cells left longer in AFM usually took 2 – 4 weeks to
start growing exponentially again (Figure 5A). This experiment
went for 27 days, by which time the cultures rescued after 8 and 9
days had not recovered. However, around 40 days later these
cultures also rapidly grow. In subsequent experiments where cells
were deprived for 14 days, a small percentage of wells (an average
of B2 – 3 per 12-well plate) showed that growth had resumed
between 3 and 4 weeks after rescue (see Discussion).
Recombinant human arginase and ADC
The two preparations of recombinant human arginase expressed in
E. coli had considerably higher specific activities than commer-
cially available preparations of non-human enzymes (Table 2;
Ikemoto et al, 1990). However, growth kinetics were affected in
both HeLa and L1210 cell lines in a manner similar to any of the
enzymes used in this study when they were given at equivalent
units of activity (Figure 6A), all of which were fully effective for
43 days at 371C. Pegylation of arginase reduces its activity
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Figure 5 (A) Effect of human recombinant arginine decarboxylase on L1210 cells. The data show the pronounced inhibition of growth of L1210 cells in
the presence of this enzyme at 1 unit ml1 (J), which is the same as in the negative control cells in AFM (&). Note that the 0.4 mM citrulline rescue (n)
gives onlyB40% of the growth rate of the positive control (’), the difference being highly significant from positive controls lacking the enzyme (P50.01),
but also equally significant in extent against the unrescued control. (B) L1210 cells were treated with 1 unit ml1 human recombinant arginase for periods up
to 27 days, but rescued by medium change into complete RPMI 1640 with 10% normal foetal calf serum at 1 (’), 2 (&), 3 (K), 4 (J), 6 (m), 7 (n), 8 (~)
and 9 (}) days. Recovery in the last two cases finally occurred at around 40 days (not shown), but the kinetics were not followed by cell counts.
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(Savoca et al, 1984), and our pegylation produced a 60% fall in
activity (Figure 6B); thus it took over twice as long to reduce
arginine to below detectable levels in our assay (i.e. o0.5 nmol).
Pegylated arginase was more stable than the unpegylated form, and
persisted without diminished vigour in culture for at least 8 days
and probably a lot longer. This is evidenced by the fact that adding
arginine to pegylated arginase-treated L1210 cells and leaving them
for periods of up to 2 weeks did not permit recovery when arginine
was restored at 0.4 mM.
Recombinant ADC worked as effectively as the Sigma prepara-
tion, giving almost identical data at equivalent units per millilitre.
In contrast to arginase, pegylation of recombinant arginine
decarboxylase completely abolished its catabolic activity.
DISCUSSION
In vitro work shows that arginine withdrawal can have a
devastating effect on malignant cells relative to normal cells,
irrespective of whether deprivation is achieved by straightforward
manipulation of the medium or in situ enzymatic catabolism of
arginine. This exercise is easy to carry out in vitro, but similar
control over the availability of arginine in vivo will need to be
gained. However, using enzymes as a treatment is going to be a
more practical proposition than, for example, extensive dialysis of
the blood (Takaku et al, 1993). Although the behaviour of a
tumour in the body may not accord with their responses in vitro
for many obvious reasons, we need to demonstrate that it does
work as well in principle with enzymes as with deficient medium,
already indicated in some previous reports (Storr and Burton,
1974; Terayama et al, 1982; Savoca et al, 1984; Miyazaki et al, 1990;
Gong et al, 2000; Wheatley et al, 2002).
Enzymes as potential therapeutic agents
The action of arginase is relatively swift and its capacity high
(Figure 2B); it therefore clears the medium of arginine relatively
quickly. Theoretically, the rate of the reaction at 1 unit ml1
converts 1 mmol arginine to B1 mmol ornithine per minute
(Figure 6A). In a medium or solution containing 400mM arginine,
each millilitre contains 0.4 mmol. In the presence of 1 unit of
arginase, just 20 s should suffice to complete the conversion to
ornithine. However, this calculation is based on arginase reacting
with excess (4 mM) arginine under the conditions of a biochemical
assay. The rate of conversion at low concentrations is slower,
mainly because arginase has a high Km (Table 2). In following the
actual conversion rate in vitro with 40, 100, 400 and 1000mM
arginine in PBS, it took about 20 – 50 min for the reaction to go to
completion at 371C. If many other amino acids are present, as in
RPMI-1640, this time can be extended by a factor of 2 – 3, and
even further when allowance is made for interference from 5%
dialysed serum. Thus, it is in keeping with amino-acid analysis
data that enzyme degradation takes at least an hour from the time
of addition of enzyme to reach 105 M levels and between 3 and 6 h
to be brought to negligible levels (106 M or less). We also know
that HeLa cells do poorly when grown in medium containing
105 M mM arginine (Wheatley et al, 2000), and therefore depres-
sion of growth should begin to be felt within an hour or two.
The product of arginase, ornithine, has the advantage that it
cannot be reconverted in vitro to arginine by cells other than
hepatocytes and a few minimal deviation hepatomas (Sugimura
et al, 1992), which will happen in the body unless liver and kidney
function are seriously compromised. In some respects this makes
arginase less attractive in therapy, but it is still possible that the
ornithine reconversion is too slow or quantitatively too small to
maintain adequate arginine levels, and that the enzyme would still
have some (restricted) action.
A disadvantage of ornithine could be its feedback inhibition of
arginase (Schimke, 1964). However, no build-up of ornithine in
cultures occurred to levels that noticeably reduced the efficacy of
arginase. This is almost certainly because the enzyme was added
exogenously and had not been produced and released in situ, as
seen in the body following liver injury. Here, a feedback
mechanism operates to reduce the translation of the arginase
mRNA, which will give control over its copy number per cell, a
situation that has yet to be modelled in vitro. Clearly, this does not
happen when ornithine is generated freely outside the cell.
Pegylation definitely assisted in prolonging the half-life of
arginase at 371C by at least a factor of considerably more than two,
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Figure 6 (A) Human recominant arginase prepared by Ikemoto et al
(1990) was divided into two batches and compared with regard to
inhibition of L1210 cells over two days, showing a dose-dependent effect
similar to Figure 8 for HeLa cells. One of these batches was pegylated and
compared with the other in terms of the breakdown of arginine to
ornithine in the next figure. (B) Alterations in the levels of arginine and
ornithine in RPMI medium measured in the amino-acid analyser after
incubation for 5 and 10 min, to show their relative rates of arginine loss in
unpegylated (’) and (&) pegylated enzyme, and correspondingly the rise
in ornithine in unpegylated (K) and pegylated (J) arginase treatment set
at precisely 1 unit ml1 of the original preparation in both cases.
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although accurate assessments have yet to be made with time that
clearly extends to weeks at 371C. It is noteworthy that arginine
deiminase can similarly be pegylated (Galea et al, 1996), but
unfortunately arginine decarboxylase cannot (Table 2). The purity
of arginase is high, and since it is activated at 601C, most other
proteins come out of solution and any contaminating enzymes are
more likely to be inactivated. We have run many experiments with
5% dialysed serum in the medium, and have found that there is no
need to give additional Mn2+ in order to improve catalytic activity,
and most preparations have been lyophilised with manganous salts
present (Roholt and Greenberg, 1956). The strong inhibition of
tumour cells by arginase indicates that it should be a very effective
antitumour agent for treating animals, provided this effect can be
translated into an effective in vivo protocol, as would seem
possible from the work of Storr and Burton (1974), who obtained
considerable tumour reduction after a remarkably short treatment
time (3 – 4 days).
In contrast, arginine decarboxylase produces agmatine (Galea
et al, 1996), which has the advantage both in vivo and in vitro of
not being recycled to arginine. The bovine enzyme was as effective
as the human recombinant form, and as arginase a unit for unit
basis, but the former’s specific activity could be up to two, if not
three, orders of magnitude less than that of human recombinant
arginase (Table 2). Therefore, much more protein would have to be
injected into animals to produce the same effect, which might
create a problem if the preparation was significantly immunogenic.
Our data indicate no obvious problem with agmatine toxicity in
culture (Figure 2C), except when it exceeded millimolar levels in
the absence of arginine, and therefore some doubt remains as to
whether a build-up under such conditions is accompanied by toxic
sequelae in the body. Agmatine had toxic effects similar to those
on HeLa cells on other cell lines, but its mode of action is not fully
understood, although because it interferes with imidazoline
receptor binding, it might block calcium channels (Santos et al,
2001). Interestingly, it is less toxic than spermidine, according to
Katsuta et al. (1975), which may explain why it is needed at
millimolar levels in the absence of arginine to have any effect.
However, agmatine is a small molecule that might be quickly
cleared. While in some respects arginine decarboxylase could be an
attractive enzyme to use, agmatine is also known to inhibit nitric
oxide synthase (Galea et al, 1996). Furthermore, this enzyme
requires pyridoxal-5-phosphate as a cofactor, but in culture we
have found good activity in media where no additional cofactor
was supplied. The downside of this enzyme, however, is that it is
inactive following pegylation (Table 2), which is probably because
of too few lysine side chains being available for attachment, and
the few that are pegylated alter its conformation too drastically to
retain activity. On balance, therefore, arginase remains the better
candidate for in vivo use (Wheatley et al, 2002; Wheatley, 1998).
But there is another enzyme with some current popularity that
we have not ourselves had available to compare throughout these
studies, viz arginine deiminase. However, this third enzyme,
prepared from cultures of Mycoplasma arginini, needs careful
consideration before it can be considered of any value in tumour
therapy because of some of the complications it produces. The
enzyme’s ability to degrade arginine explains why some myco-
plasma infections can have devastating effects on cell growth
(Terayama et al, 1982), but this is not confined to tumour cells.
Unfortunately, a strict comparison of its catabolic activity relative
to arginase and arginine decarboxylase has not yet been carried
out in this regard, but we hope to report on this later. It is also
claimed to be more effective than L-asparaginase against leukaemic
cells in vitro (Gong et al, 2000), but this report took no account of
their relative specific activities (Wheatley et al, 2002). It also
apparently killed cells more effectively in arginine-containing
medium than in AFM, which is incompatible with its primary
action being through arginine deprivation. The product of arginine
deiminase is citrulline, which will be quickly converted back to
arginine both in vivo and in vitro, which further weakens this
explanation, just as it does in other similar claims (Miyazaki et al,
1990; Sugimura et al, 1992; Takaku et al, 1992, 1993). Therefore,
the only truly rational explanation remaining is that the reaction
generates ammonia. In cultures, where ammonia cannot be
detoxified, small traces of the free gas can be lethal to both
normal and tumour cells. The irony is that arginine itself is
required to assist in the detoxification of ammonia. We do note,
however, that some cells are incapable of utilising citrulline instead
of arginine (Campbell et al, in press), and these might prove to be
more susceptible to arginine deiminase provided it can be effective
when arginine concentration is not too high (so that ammonia
generation is limited).
Complications with nitric oxide (NO) metabolism
One further enzyme might also be further mentioned, viz nitric
oxide synthase (Wu and Morris, 1998). This produces citrulline
and NO from arginine, but this arginine has to be channelled
initially from citrulline in what amounts to a tight circular
coupling (Chang et al, 2001). It is of little use, therefore, as a
catabolic enzyme, especially with an extremely low Km (Tables 1
and 2; Tatoyan and Giulivi, 1998), and its ability to deal with only
nanomolar quantities of arginine shows it to be both inadequate
and inappropriate. One apparent problem with arginine-catabolis-
ing enzymes such as arginase is that removal of arginine from the
body was originally thought to deprive NO synthase of its
substrate, and lead to loss of vascular tone and signalling in many
other vital functions. However, new evidence strongly suggests that
a special arginine pool may be generated, which is closely linked or
channelled with nitric oxide synthase in appropriate cells (Flam
et al, 2001).
Implications for future applications
We still face problems with tumours and their hosts that are good
converters of citrulline to arginine, although we have also clearly
shown here (and the work in progress) that citrulline conversion
cannot so often keep up with arginine demands of the faster-
growing tumour cells. The most suitable subjects for treatment
both in culture and in vivo will undoubtedly be those tumours that
are poor converters, for example, certain hepatomas and
melanomas (Sugimura et al, 1992).
A further problem that cannot be ignored in this complicated
scenario is the control of the breakdown of nonessential proteins
by the cells of the body (Grisolı´a and Wheatley, 1984), which can
release amino acids in sufficient quantity to circumvent the best
efforts to induce a true arginine-deficient state. We also do not
know how much this, and scavenging from dead cells, plays a part
in keeping at least some cells alive in arginine deprivation
conditions after many days (Figure 5B). Some procedures can be
introduced to help reduce protein breakdown, and these might be
needed alongside the catabolic enzymes, although if the findings of
Takaku et al (1993) are correct, pegylated arginine deiminase can
keep arginine below detectable levels for at least 8 days in mice
injected i.v. with a single bolus of 5 units of enzyme. Thus, it is
difficult to assess the extent to which enzyme-induced deprivation
will be affected by protein turnover without many more careful
studies. Nevertheless, some cells can and do survive enzyme
treatment or AFM in culture, even if these are very exceptional
cases, after a period of a week or more of exposure. We are
convinced that the only cells that seem to persist for any length of
time are the very large multinucleated and often highly polyploid
cells, as seen in HeLa and L1210 cultures (Figure 3). If Erenpreisa
and Cragg (2001) are correct, then these large cells, similar to those
surviving apparently lethal doses of radiation, may later undergo
‘reduction divisions’, creating one or two small progenitor cells
that repopulate the cultures. However, it will take time to
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determine whether this is indeed the mechanism that also occurs
in our cultures after arginine deprivation.
CONCLUSION
We conclude that enzymatic degradation is a reasonable procedure
for removing arginine from culture media, and this has also been
shown to be effective in vivo by others, especially in pegylated
forms of arginine deiminase and arginase. However, each enzyme
has its shortcomings, and additional strategies will be needed to
circumvent them. Arginase remains a strong contender, however,
because of its high specific activity, and production of ornthinine
rather than citrulline (Wheatley et al, 2002). The major obstacles
are, (i) efficient recycling where an intact urea cycle operates,
leaving only some of those in which the urea cycle has been
compromised as susceptible, and (ii) in the large-scale protein
turnover that can easily subvert efforts to maintain free arginine at
micromolar levels.
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